We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Mgc Pharmaceuticals Limited | LSE:MXC | London | Ordinary Share | AU000000MXC6 | ORD NPV (DI) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 22.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Drug & Proprietary Stores | 4.16M | -20.82M | -0.4749 | -0.91 | 18.86M |
From Apr 2023 to Apr 2024
TIDMMXC
RNS Number : 9127Z
MGC Pharmaceuticals Limited
18 May 2023
MGC Pharmaceuticals Ltd.
PDMR Notification
18 May 2023
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes to advise that the following Persons Discharging Managerial Responsibilities (PDMR) have dealt with shares in MGC Pharma, and this notification is made in accordance the UK Market Abuse Regulations.
Hot Features
Premium
1 Details of the person discharging managerial responsibilities/person
closely associated
(a) Name Nicole Godresse
--------------------------------------- -----------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
(a) Position Global Chief Sales Officer MGC
Medical
--------------------------------------- -----------------------------------
(b) Initial notification/amendment Initial
--------------------------------------- -----------------------------------
(c) If amendment: reason n/a
--------------------------------------- -----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
Full name of entity MGC Pharmaceuticals Limited
--------------------------------------- -----------------------------------
Legal Entity Identifier 213800HRE3FQJ6RK4H10
Code
--------------------------------------- -----------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; (iv) each place where transactions
have been conducted
----------------------------------------------------------------------------
(a) Description of the financial Fully Paid Ordinary Shares
instrument, type of
instrument
--------------------------------------- -----------------------------------
(b) Identification Code AU000000MXC6
(ISIN)
--------------------------------------- -----------------------------------
(c) Nature of transaction Disposal of shares
--------------------------------------- -----------------------------------
(d) Currency Price Volume Total
------------------ ------------------- ------------- --------------------
AUD $0.007 876,636 $6,136
------------------------ ------------------- ------------- --------------------
Aggregated information
----------------------------------------------------------------------------
AUD $0.007 876,636 $6,136
------------------------ ------------------- ------------- --------------------
(e) Date of transaction 2023-05-16
--------------------------------------- -----------------------------------
(f) Place of transaction Australian Stock Exchange
--------------------------------------- -----------------------------------
1 Details of the person discharging managerial responsibilities/person
closely associated
(a) Name Amir Polak
--------------------------------------- -----------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
(a) Position Chief Pharmaceutical Development
Officer
--------------------------------------- -----------------------------------
(b) Initial notification/amendment Initial
--------------------------------------- -----------------------------------
(c) If amendment: reason n/a
--------------------------------------- -----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
Full name of entity MGC Pharmaceuticals Limited
--------------------------------------- -----------------------------------
Legal Entity Identifier 213800HRE3FQJ6RK4H10
Code
--------------------------------------- -----------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; (iv) each place where transactions
have been conducted
----------------------------------------------------------------------------
(a) Description of the financial Fully Paid Ordinary Shares
instrument, type of
instrument
--------------------------------------- -----------------------------------
(b) Identification Code AU000000MXC6
(ISIN)
--------------------------------------- -----------------------------------
(c) Nature of transaction Disposal of shares
--------------------------------------- -----------------------------------
(d) Currency Price Volume Total
------------------ ------------------- ------------- --------------------
AUD $0.007 500,000 $3,500
------------------------ ------------------- ------------- --------------------
Aggregated information
----------------------------------------------------------------------------
AUD $0.007 500,000 $3,500
------------------------ ------------------- ------------- --------------------
(e) Date of transaction 2023-05-17
--------------------------------------- -----------------------------------
(f) Place of transaction Australian Stock Exchange
--------------------------------------- -----------------------------------
--Ends-
Authorised for release by the Managing Director, for further information please contact:
MGC Pharmaceuticals Ltd MGC Pharmaceuticals Ltd Roby Zomer Arron Canicais / Rowan Harland CEO & Managing Director Joint Company Secretaries +61 8 6382 3390 +61 8 6382 3390 info@mgcpharma.co.uk info@mgcpharma.co.uk UK PR Advisors UK Brokers Tavistock Peterhouse Capital Charles Vivian / Tim Pearson Charles Goodfellow / Lucy Williams +44 207 920 3150 +44 207 469 0930 mgcpharma@tavistock.co.uk cg@peterhousecap.com / lw@peterhousecap.com UK Financial and Corporate Advisor SW4 Partners Rupert Fane / Nilesh Patel rupert@sw4partners.com / nilesh@sw4partners.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBGGDULUBDGXI
(END) Dow Jones Newswires
May 18, 2023 07:00 ET (11:00 GMT)
1 Year Mgc Pharmaceuticals Chart |
1 Month Mgc Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
